Voyager Enters into License for Next-Generation Capsid

 

Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE: NVS) has agreed to license a novel capsid generated from Voyager’s TRACER™ capsid discovery platform for use in a gene therapy program against an undisclosed rare neurologic disease target. This capsid license is being granted pursuant to the agreement between Voyager and Novartis originally announced in March 2022.

https://www.globenewswire.com/news-release/2024/09/05/2941289/36461/en/Voyager-Enters-into-License-for-Next-Generation-Capsid-Bringing-Partnered-Portfolio-of-TRACER-Enabled-Gene-Therapies-to-14.html